Literature DB >> 19253365

Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis.

Wim Ceelen1, Kjell Fierens, Yves Van Nieuwenhove, Piet Pattyn.   

Abstract

Combining chemotherapy with preoperative radiotherapy (RT) has a sound radiobiological rationale. We performed a systematic review and meta-analysis of trials comparing preoperative RT with preoperative chemoradiation (CRT) in rectal cancer patients. The Cochrane Central Register of Controlled Trials, Web of Science, Embase and Medline (Pubmed) were searched from 1975 until June 2007. Dichotomous parameters were summarized using the odds ratio while time to event data were analyzed using the pooled hazard ratio for death. From the primary search result of 324 trials, 4 relevant randomized trials were identified. The addition of chemotherapy significantly increased grade III and IV acute toxicity (p = 0.002) while no differences were observed in postoperative morbidity or mortality. Preoperative CRT significantly increased the rate of pathological complete response (p < 0.001) although this did not translate into a higher sphincter preservation rate (p = 0.29). The local recurrence rate was significantly lower in the CRT group (p < 0.001). No statistically significant differences were observed in disease free survival (p = 0.89) or overall survival (p = 0.79). Compared to preoperative RT alone, preoperative CRT improves local control in rectal cancer but is associated with a more pronounced treatment related toxicity. The addition of chemotherapy does not benefit sphincter preservation rate or long-term survival. Future trials should address improvements in the rate of distant metastasis and overall survival by incorporating more active chemotherapy. Copyright 2008 UICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19253365     DOI: 10.1002/ijc.24247

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer.

Authors:  Wang Jianyang; Tian Yuan; Tang Yuan; Wang Xin; Li Ning; Ren Hua; Fang Hui; Feng Yanru; Wang Shulian; Song Yongwen; Liu Yueping; Wang Weihu; Li Yexiong; Jin Jing
Journal:  Radiol Med       Date:  2015-11-27       Impact factor: 3.469

2.  Diffusion-weighted magnetic resonance imaging for prediction of tumor response to neoadjuvant chemoradiotherapy using irinotecan plus S-1 for rectal cancer.

Authors:  Hiroshi Doi; Naohito Beppu; Takashi Kato; Masashi Noda; Hidenori Yanagi; Naohiro Tomita; Norihiko Kamikonya; Shozo Hirota
Journal:  Mol Clin Oncol       Date:  2015-07-21

3.  Evidence based radiation oncology with existing technology.

Authors:  Nicolas Isa
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-14

Review 4.  Interval to surgery after neoadjuvant treatment for colorectal cancer.

Authors:  Nir Wasserberg
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

5.  Laparoscopic TME associated with neoadjuvant chemoradiation towards aggressive colorectal cancer.

Authors:  Tao Yin; Dian-Sheng Cui; Zhi-Guo Xiong; Shao-Zhong Wei
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 6.  Update on advances and controversy in rectal cancer treatment.

Authors:  S Biondo; D Fraccalvieri; T Golda; R Frago; L Trenti; E Kreisler
Journal:  Tech Coloproctol       Date:  2016-01-12       Impact factor: 3.781

7.  Locally advanced mid/low rectal cancer with synchronous liver metastases.

Authors:  Luca Viganò; Mehdi Karoui; Alessandro Ferrero; Claude Tayar; Daniel Cherqui; Lorenzo Capussotti
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 8.  Locally advanced rectal cancer: a comparison of management strategies.

Authors:  Robert Glynne-Jones; Miranda Kronfli
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

9.  Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.

Authors:  Anthony C Wong; Shannon Stock; Deborah Schrag; Katherine L Kahn; Talya Salz; Mary E Charlton; Selwyn O Rogers; Karyn A Goodman; Nancy L Keating
Journal:  J Oncol Pract       Date:  2014-07-01       Impact factor: 3.840

Review 10.  Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer.

Authors:  Omer Jalil; Leica Claydon; Tan Arulampalam
Journal:  J Gastrointest Cancer       Date:  2015-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.